Eckert & Ziegler: capital increase successfully concluded / clear oversubscription
Eckert & Ziegler Strahlen- und Medizintechnik AG / Capital Increase
04.12.2009
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Berlin, December 4th, 2009. -- The Berlin based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) has successfully concluded its capital increase for cash. The company has increased its capital stock by 34.5%. 1,350,000 shares were thereby placed at a subscription price of 15.95 EUR each. The new shares were placed to the shareholders of the company and interested investors within the framework of a private placement. The subscription period ended on 3 December 2009. After registering and implementing the capital increase in the commercial register the capital stock amounts to 5,260,283.00 EUR, divided into 5,260,283 shares.
After the completion of the securities prospectus the new shares will be permitted to be traded on the Frankfurt Stock Exchange (Prime Standard). The company intends to effect the listing of the new shares still in December 2009.
With the capital gross inflow of around 21.5 million EUR flow into the company that will be used in particular for the extension of the Environmental Services segment as well as any arising acquisition opportunities.
Information and Explaination of the Issuer to this News:
'The clear oversubscription in excess underlines the great trust investors have in the company and our business model', explained Dr Andreas Eckert, Chief Executive Officer at Eckert & Ziegler AG.
The capital increase was accompanied by BankM - representation of biw Bank für Investments und Wertpapiere AG.
Eckert & Ziegler AG focuses on advanced technologies in the field of radioisotopes and with its approx. 520 employees it is one of the largest producers of radioactive components for science, medicine and industry worldwide. The company, which is listed on the stock exchange, expects a turnover of 100 million EUR and earnings per share of some 1.80 EUR in 2009.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.com
04.12.2009 Financial News distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service